New entrants could disrupt “tough” fertility market

The cost-of-living crisis is having a huge impact on fertility patients, making the sector ripe for disruption. A fertility expert tells HBI cunning new entrants will be the winners while established PE could well be the losers.

Interview: Audrey Tsang, Co-CEO, Clue

Women’s health offers a huge opportunity for investors, with conditions like endometriosis underserved. What business models can help support this? Audrey Tsang is co-CEO at women's health app company Clue. She talks to HBI about how she thinks the gender health gap might be closed.

Why KKR is set to buy Eugin – and Fresenius wants to sell

Global investment company KKR is set to buy Eugin, the Spain-based fertility subsidiary owned by Germany-based conglomerate Fresenius, for €500m. We ask why KKR might want it, and whether it makes sense for Fresenius to sell.

KKR set to buy Eugin for €500m

US-based global investment company KKR looks set to buy Eugin, the Spain-based fertility group owned by Germany-based conglomerate Fresenius, with which it is reportedly in exclusive talks. The deal values Eugin at around €500m.

Private pay: Rising – but not as fast as you think

Data from the Private Healthcare Information Network (PHIN) shows the self-pay bubble in the UK seems to have reached its peak. While private pay admissions are still rising across the country, self-pay is out while private medical insurance (PMI) is in.

Helios CEO Francesco De Meo leaves with little fanfare

Fresenius Helios has a new CEO. Germany’s largest hospital group by revenue and subsidiary of Germany-based conglomerate Fresenius announced the news in a press release which ignores outgoing Francesco De Meo’s significant and longstanding contribution to the group.

Find Us